{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024677","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.681116+00:00","generated_at":"2026-06-21T19:51:49.650934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acasti Pharma Q2 FY2023: net loss $4.9M; cash $34.9M; advances three clinical programs","bullets":["Net loss $4.9M ($0.11/sh) vs net income $1.0M in prior-year quarter; operating loss $5.1M.","R&D expenses rose to $3.3M from $0.6M due to PK studies for GTX-104, -102, -101.","Cash & short-term investments $34.9M as of Sep 30, 2022, down from $43.7M at Mar 31, 2022; runway through at least Mar 2024.","FDA Type C meeting on GTX-104 Phase 3 design expected by end of 2022/early Q1 2023; GTX-102 and GTX-101 PK topline results by end of 2022.","Vimal Kavuru appointed Chairman of the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024677","json":"https://secwatch.observer/filing/0000950170-22-024677.json","markdown":"https://secwatch.observer/filing/0000950170-22-024677.md","text":"https://secwatch.observer/filing/0000950170-22-024677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017022024677/0000950170-22-024677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017022024677/acst-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:51:49.650934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8da8ca71c5ace8ade3e80c86c107cc762731ebbd","claim":"Grace Therapeutics, Inc. reported financial results for the second quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017022024677/0000950170-22-024677-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}